Sorafenib Therapy for Metastatic Renal Carcinoma in Patients with Low Cardiac Ejection Fraction: Report of Two Cases and Literature Review

REFERENCES

• Rosenberg, S.A.; Yang, J.C.; White, D.E.; Stenberg, S.M. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg 1998, 228(3), 307–319.
   PubMed Web of Science ®Google Scholar
• Kammula, U.S.; White, D.E.; Rosenberg, S.A. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer 1998, 83, 797–805.
   PubMed Web of Science ®Google Scholar
• Daher, I.N.; Yeh, E.T. Vascular complications of selected cancer therapies. Nat Clin Pract Cardiovasc Med 2008, 5(12), 797–805.
   PubMedGoogle Scholar
• Miller, K.D.; Chap, L.I.; Holmes, F.A.; Cobleigh, M.A.; Marcom, P.K.; Fehrenbacher, L.; Dickler, M.; Overmoyer, B.A.; Reimann, J.D.; Sing, A.P.; Langmuir, V.; Rugo, H.S. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005, 23(4), 792–799.
   PubMed Web of Science ®Google Scholar
• Chu, T.F.; Rupnick, M.A.; Kerkela, R.; Dallabrida, S.M.; Zurakowski, D.; Nguyen, L.; Woulfe, K.; Pravda, E.; Cassiola, F.; Desai, J.; George, S.; Morgan, J.A.; Harris, D.M.; Ismail, N.S.; Chen, J.H.; Schoen, F.J.; Van Den Abbeele, A.D.; Demetri, G.D.; Force, T.; Chen, M.H. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007, 370(9604), 2011–2019.
   PubMed Web of Science ®Google Scholar
• Khakoo, A.Y.; Kassiotis, C.M.; Tannir, N.; Plana, J.C.; Halushka, M.; Bickford, C.; Trent, J. 2nd; Champion, J.C.; Duraud, J.B.; Lenihan, D.J.; Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer 2008, 112, 2500–2508.
   PubMed Web of Science ®Google Scholar
• Di Lorenzo, G.; Autorino, R.; Bruni, G.; Cartenì, G.; Ricevuto, E.; Tudini, M.; Ficorella, C.; Romano, C.; Aieta, M.; Giordano, A.; Giuliano, M.; Gonnella, A.; De Nunzio, C.; Rizzo, M.; Montesarchio, V.; Ewer, M.; De Placido, S. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol 2009, 20(9), 1535–1542.
   PubMed Web of Science ®Google Scholar
• Schmidinger, M.; Zielinski, C.C.; Vogl, U.M.; Bojic, A.; Bojic, M.; Schukro, C.; Ruhsam, M.; Hejna, M.; Schmidinger, H. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008, 26(32), 5204–5212.
   PubMed Web of Science ®Google Scholar
• Pfizer Canada Inc. SUTENT product monograph. Canada: Pfizer Inc., 2006.
   Google Scholar
• Kollmannsberger, C.; Soulieres, D.; Wong, R.; Scalera, A.; Gaspo, R.; Bjarnason, G. Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Can Urol Asso J 2007, 1(2 Suppl), s41–s54.
   PubMed Web of Science ®Google Scholar
• Khakooa, A.; Masseya, M.; Chuaa, C.; Chiua, A.; Mouhayera, E.; Duranda, J.B.; Lenihana, D.J. Hypertension, potentially leading to heart failure, associated with anti-vascular endothelial growth factor therapy can be predicted by baseline risk factors and serial B-type natriuretic peptide levels during treatment. J Card Fail 2009, 15(6), Supplement 1, S65.
   Web of Science ®Google Scholar
• Escudier, B.; Eisen, T.; Stadler, W.M.; Szczylik, C.; Oudard, S.; Staehler, M.; Negrier, S.; Chevreau, C.; Desai, A.A.; Rolland, F.; Demkow, T.; Hutson, T.E.; Gore, M.; Anderson, S.; Hofilena, G.; Shan, M.; Pena, C.; Lathia, C.; Bukowski, R.M. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009, 27(20), 3312–3318.
   PubMed Web of Science ®Google Scholar
• Nexavar [package insert]. Wayne, N.J. Bayer HealthCare Pharmaceuticals, Inc. and Emeryville, CA: Onyx Pharmaceuticals, Inc. 2008.
   Google Scholar
• Veronese, M.L.; Mosenkis, A.; Flaherty, K.T.; Gallagher, M.; Stevenson, J.P.; Townsend, R.R.; O’Dwyer, P.J. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 2006 Mar 20, 24(9), 1363–1369.
   PubMed Web of Science ®Google Scholar
• Tolcher, A.; Appleman, L.; Mita, A.; Shapiro, G.; Cihon, F.; Mazzu, A.; Sundaresan, P.R. Effect of sorafenib treatment on left ventricular ejection fraction and other cardiovascular safety parameters in cancer patients: an open-label, phase I study. Presented at the 33rd Congress of the European Society for Medical Oncology; September 12–16, 2008; Stockholm, Sweden.
   Google Scholar
• Maitland, M.L.; Kasza, K.E.; Karrison, T.; Moshier, K.; Sit, L.; Black, H.R.; Undevia, S.D.; Stadler, W.M.; Elliott, W.J.; Ratain, M.J. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res 2009, 15, 6250–6257.
   PubMed Web of Science ®Google Scholar
• Eisen, T.; Beck, J.; Procopio, G.; Negrier, S.; Keilholz, U.; von der Maase, H.; Strauss, U.P.; Burock, K.; Mersmann, S.; Escudier, B. A large open-label noncomparative phase III study of sorafenib in European patients with advanced RCC (EU-ARCCS) – Subgroup analysis of patients with and without baseline clinical cardiovascular diseases (CCD). Presented at the 33rd Congress of the European Society for Medical Oncology; September 12–16, 2008; Stockholm, Sweden.
   Google Scholar
• Harshman, L.C.; Witteles, R.M.; Telli, M.P.; Srinivas, S. Low incidence of symptomatic cardiotoxicity associated with sorafenib in patients with metastatic renal cell carcinoma (mRCC): An institutional experience. Presented at the American Society of Clinical Oncology 2009 Genitourinary Cancers Symposium; February 26–28, 2008; Orlando, FL.
   Google Scholar
• Mego, M.; Reckova, M.; Obertova, J.; Sycova-Mila, Z.; Brozmanova, K.; Mardiak, J. Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma. Ann Oncol 2007, 18, 1906–1907.
   PubMed Web of Science ®Google Scholar
• Wong, M.K.; Jarkowski, A. Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature. Pharmacotherapy 2009, 29(4), 473–478.
   PubMed Web of Science ®Google Scholar
• Markel, T.A.; Wang, Y.; Herrmann, J.L.; Crisostomo, P.R.; Wang, M.; Novotny, N.M.; Herring, C.M.; Tan, J.; Lahm, T.; Meldrum, D.R. VEGF is critical for stem cell-mediated cardioprotection and a crucial paracrine factor for defining the age threshold in adult and neonatal stem cell function. Am J Physiol Heart Circ Physiol 2008, 295(6), H2308–H2314.
   PubMed Web of Science ®Google Scholar
• Guzman, M.J.; Crisostomo, P.R.; Wang, M.; Markel, T.A.; Wang, Y.; Meldrum, D.R. Vascular endothelial growth factor improves myocardial functional recovery following ischemia/reperfusion injury. J Surg Res 2008, 150(2), 286–292.
   PubMed Web of Science ®Google Scholar
• Sasso, F.C.; Torella, D.; Carbonara, O.; Ellison, G.M.; Torella, M.; Scardone, M.; Marra, C.; Nasti, R.; Marfella, R.; Cozzolino, D.; Indolfi, C.; Cotrufo, M.; Torella, R.; Salvatore, T. Increased vascular endothelial growth factor expression but impaired vascular endothelial growth factor receptor signaling in the myocardium of type 2 diabetic patients with chronic coronary heart disease. J Am Coll Cardiol 2005, 46(5), 827–834.
   PubMed Web of Science ®Google Scholar
• Force, T.; Krause, D.S.; Van Etten, R.A. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007, 7(5), 332–344.
   PubMed Web of Science ®Google Scholar
• Hasinoff, B.B.; Patel, D.; O’Hara, K.A. Mechanisms of myocyte cytotoxicity induced by the multiple receptor tyrosine kinase inhibitor sunitinib. Mol Pharmacol 2008, 74(6), 1722–1728.
   PubMed Web of Science ®Google Scholar
• Will, Y.; Dykens, J.A.; Nadanaciva, S.; Hirakawa, B.; Jamieson, J.; Marroquin, L.D.; Hynes, J.; Patyna, S.; Jessen, B.A. Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells. Toxicol Sci 2008, 106(1), 153–161.
   PubMed Web of Science ®Google Scholar